Anas Hamad: The first study in the MENA region to compare the 3 CDK4/6 Inhibitors in one analysis

Anas Hamad, Director of Pharmacy Department at National Center for Cancer Care and Research, shared on LinkedIn:

“Happy to share our latest publication ‘Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov’s model-based evaluation’ which was just published in the esteemed Frontiers in Oncology Q1 Journal.

This is the first study in the MENA (Middle East and North Africa) region to compare the 3 CDK4/6 Inhibitors in one analysis. We believe our results can be useful for similar healthcare systems in the GCC and beyond.

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov’s model-based evaluation

Thanks to the amazing research team for their great contributions: Shereen Elazzazy, Nour Hisham A., Mohamed Izham Mohamed Ibrahim, Salha Bujassoum Albader.”

Source: Anas Hamad/LinkedIn